THE ARISING · Longevity & Healthspan · Long Reads
Two Brain-Aging Studies Are Listed: Baltimore PET Imaging and a VR Driving Game
One study plans to follow brain amyloid and tau in 400 healthy older volunteers for years; the other tests whether a virtual driving game helps 20 people with advanced dementia. Neither has results yet, and they answer very different questions.
The amyloid plaques of Alzheimer's disease start building years before memory slips. Two registered studies attack cognitive aging from opposite ends. One watches the brain change in people who are still well. The other tries to bring a moment of engagement to people who are already deeply affected.
Our research desk flagged two entries on ClinicalTrials.gov. The first is a PET imaging study run inside the Baltimore Longitudinal Study of Aging, sponsored by the National Institute on Aging. The second is a University of Manitoba study of an augmented virtual reality driving simulator for people living with dementia in care.
Neither registry record has posted results. Registry absence alone does not establish that no findings have been presented elsewhere.
THE FEDERAL BRAIN-IMAGING COHORT
The registry record, NCT07099053, lists the National Institute on Aging as sponsor and a target of 400 participants. The record has been retitled "PET Imaging in the Baltimore Longitudinal Study of Aging (BLSA)" and now includes tau PET with [18F]florquinitau (Tauklarify) alongside florbetaben amyloid PET, so it is no longer an amyloid-only study. Volunteers must be at least 55 and already enrolled in the Baltimore study, which has followed healthy adults since 1958.
Participants get PET/CT scans with intravenous tracers that make amyloid and tau visible. Scans recur every one to four years depending on age, and yearly from age 80. Each scan takes roughly 30 minutes of lying still. The November 10 registry update lists the study as recruiting and gives November 15, 2026 as its start date. Recruitment status and the first imaging date are different facts. Estimated completion is December 12, 2029.
The value here is the setting, not the scan. The Baltimore study already collects detailed cognitive, physical and medical data on the same people over decades. Adding repeated PET imaging lets researchers ask when amyloid appears, how fast it builds, and whether it tracks with brain structure, cognition or other illness.
THE VR DRIVING STUDY
The Manitoba record, NCT06419257, plans to enroll 20 residents of a dementia care unit at Riverview Health Centre in Winnipeg. Participants must be 50 or older, mobile and able to see. Wheelchair users are excluded.
The simulator is built into an existing car body, and the study will likely use only its easiest level. The outcomes are soft. The narrative describes free-form nurse observations; the registered primary outcome uses a custom questionnaire scored worse, unchanged or improved, weekly for up to 52 weeks. Researchers infer implicit memory from in-game driving scores such as curb strikes and red lights run. The study began in January 2024, and the registry lists study completion in June 2027.
Amyloid now matters clinically in a way it did not five years ago. Anti-amyloid antibodies are approved for early Alzheimer's disease, and blood tests for amyloid are entering practice. Knowing how amyloid behaves in ordinary aging adults is what lets doctors interpret a positive result in a healthy 70-year-old.
Long cohorts like Baltimore's are where those reference curves come from. They are slow, unglamorous and enormously useful.
The VR study speaks to a different need: quality of life for people whose disease is advanced. A familiar activity like driving may prompt engagement or calm. That is worth testing, but it is not a treatment for dementia.
• Success in a game is not success in life. Better driving scores could simply reflect practice on that game. Our desk made the same point, and it is the right one. • Twenty participants with no control group listed, and mood assessed through nurse observations and a custom questionnaire, can generate ideas but not proof. • The Baltimore imaging study is observational. It can show associations between brain changes and decline, not cause and effect. • The Manitoba record lists primary completion in May 2027 and study completion in June 2027. Both dates are correct; they mark different milestones.
• If you are curious about your own amyloid status, ask your physician whether testing would change any decision for you. Without symptoms, it often does not. • Keep doing the proven basics for brain health: blood pressure control, physical activity, hearing correction, sleep and social contact. • If a loved one is in memory care, ask staff about structured, familiar activities. Judge them by mood and engagement, not by game scores. • Anyone with new memory or thinking changes should see their doctor for a full evaluation.
• Early Baltimore amyloid and tau analyses, likely years away, showing brain trajectories in healthy older adults.
• Whether the Manitoba team reports outcomes beyond the game itself, such as agitation or caregiver burden. • How amyloid blood tests are calibrated against PET in cohorts like this one.